Wnt16: a new potential therapeutic target for osteoporotic non-vertebral fracture treatment

Area of Science:

• Bone Biology and Osteoporosis Research
• Molecular Mechanisms of Bone Metabolism

Background:

• Osteoporotic non-vertebral fractures pose a significant clinical challenge.
• Cortical bone deterioration is a critical, often overlooked, factor in osteoporosis pathogenesis.

Purpose of the Study:

• To review the role of Wnt16 in regulating cortical bone.
• To evaluate Wnt16 as a therapeutic target for osteoporotic non-vertebral fractures.

Main Methods:

• Systematic literature review of Wnt16 in senile, postmenopausal, and glucocorticoid-induced osteoporosis.
• Analysis of Wnt16's mechanisms: genetic associations, effects on cortical bone structure, and regulation of osteoblasts and osteoclasts.

Main Results:

• Wnt16 influences bone mineral density through genetic associations.
• Wnt16 reduces cortical bone porosity and increases thickness.
• Wnt16 modulates osteoblast and osteoclast activity via specific signaling pathways.
• Preclinical studies show Wnt16 improves bone density and reduces fracture risk, with some conflicting data in glucocorticoid-induced models.

Conclusions:

• Wnt16 is a potential therapeutic target for preventing non-vertebral fractures.
• Notum inhibitors represent a promising class of therapeutic agents for osteoporosis.
• This review provides a foundation for future clinical and translational research in Wnt16-targeted therapies.